



Berkshire West Area Prescribing Committee

Drug Name	Dutasteride plus tamsulosin (Combodart®)		
Indication under review	Treatment of benign prostatic hyperplasia (BPH)		
Policy No:	APC 074		
Date of Issue/ Date of re-issue:	January 2014/ March 2017		
Review Date:	January 2017		
Policy Statement:			
Dutasteride plus tamsulosin (Combodart®) is not routinely recommended for the treatment of Benign Prostatic Hyperplasia (BPH). Treatment may be prescribed only for patients who need both of these medications on a long term basis.			
Traffic Light Status	Brown		
Key Points considered:			
<ul style="list-style-type: none"> No comparative head to head studies found for this combination versus other combinations of an alpha blocker + 5alpha-reductase inhibitor. This combination is the most cost effective way of administering these two specific drugs but not the most cost effective way of administering an alpha blocker and an 5alpha-reductase inhibitor. Some concern that using a combination product would not allow flexibility in dosing. The patent for dutasteride (Avodart®) is likely to end in 2013 and this combination capsule is unlikely to remain the most cost effective after generic dutasteride is available. This policy has been produced as a guide for GPs. Evidence and information was carefully considered and consulted upon by clinicians who concluded that this treatment is not a cost effective use of scarce NHS resources. There are situations where this policy may not apply to an individual patient due to their clinical exceptionality. This policy statement does not overrule an individual GPs clinical decision making and therefore each GP would be need to make the final decision on whether treatment is a cost-effective use of their CCG budget 			
References:			
<ol style="list-style-type: none"> SPC accessed via www.emc.medicines.org.uk NICE accessed via www.nice.org.uk SMC accessed via www.scottishmedicines.org.uk AWMSG accessed via www.wales.nhs.uk NPCi accessed via http://www.npci.org.uk/blog/?p=1828 Montorsi F et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract. 2010 Jul;64(8):1042-51. Epub 2010 May 7. Tacklind J et al. Finasteride for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD006015. DOI: 10.1002/14651858.CD006015.pub3. 			
Date taken to APC:			1 st March 2017
Date Ratified by MOC on Behalf of the Board:			15 th March 2017

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only